Literature DB >> 23798501

Usefulness of the Montreal Cognitive Assessment (MoCA) in Huntington's disease.

Shea Gluhm1, Jody Goldstein, Daniel Brown, Charles Van Liew, Paul E Gilbert, Jody Corey-Bloom.   

Abstract

BACKGROUND: The Montreal Cognitive Assessment (MoCA) is a brief screening instrument for dementia that is sensitive to executive dysfunction. This study examined its usefulness for assessing cognitive performance in mild, moderate, and severe Huntington's disease (HD), compared with the use of the Mini-Mental State Examination (MMSE).
METHODS: We compared MoCA and MMSE total scores and the number of correct answers in 5 cognitive-specific domains in 104 manifest HD patients and 100 matched controls.
RESULTS: For the total HD sample, and for the moderate and severe patients, significant differences between both MoCA and MMSE total scores and almost all cognitive-specific domains emerged. Even mild HD subjects showed significant differences with regard to total score and several cognitive domains on both instruments.
CONCLUSIONS: We conclude that the MoCA, although not necessarily superior to the MMSE, is a useful instrument for assessing cognitive performance over a broad level of functioning in HD.
© 2013 Movement Disorder Society.

Entities:  

Keywords:  Huntington's disease; Mini-Mental State Examination (MMSE); Montreal Cognitive Assessment (MoCA); cognitive decline

Mesh:

Year:  2013        PMID: 23798501      PMCID: PMC4347861          DOI: 10.1002/mds.25578

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  11 in total

1.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

2.  CAG repeat number governs the development rate of pathology in Huntington's disease.

Authors:  J B Penney; J P Vonsattel; M E MacDonald; J F Gusella; R H Myers
Journal:  Ann Neurol       Date:  1997-05       Impact factor: 10.422

3.  The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease.

Authors:  David J Gill; Arielle Freshman; Jennifer A Blender; Bernard Ravina
Journal:  Mov Disord       Date:  2008-05-15       Impact factor: 10.338

4.  Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington's disease.

Authors:  Ondrej Bezdicek; Veronika Majerova; Marek Novak; Tomas Nikolai; Evzen Ruzicka; Jan Roth
Journal:  Appl Neuropsychol Adult       Date:  2012-10-09       Impact factor: 2.248

5.  Use of the frontal assessment battery in evaluating executive dysfunction in patients with Huntington's disease.

Authors:  Guilherme Riccioppo Rodrigues; Carolina Pinto Souza; Roberto Satler Cetlin; Daniel Sabino de Oliveira; Marcio Pena-Pereira; Liliana Tiemi Ujikawa; Wilson Marques; Vitor Tumas
Journal:  J Neurol       Date:  2009-06-18       Impact factor: 4.849

6.  A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment.

Authors:  Alex J Mitchell
Journal:  J Psychiatr Res       Date:  2008-06-24       Impact factor: 4.791

7.  Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

Authors: 
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

Review 8.  Brief cognitive screening instruments: an update.

Authors:  Zahinoor Ismail; Tarek K Rajji; Kenneth I Shulman
Journal:  Int J Geriatr Psychiatry       Date:  2010-02       Impact factor: 3.485

9.  A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease.

Authors:  Cindy Zadikoff; Susan H Fox; David F Tang-Wai; Teri Thomsen; Rob M A de Bie; Pettarusup Wadia; Janis Miyasaki; Sarah Duff-Canning; Anthony E Lang; Connie Marras
Journal:  Mov Disord       Date:  2008-01-30       Impact factor: 10.338

10.  The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease.

Authors:  Aleksandar Videnovic; Bryan Bernard; Wenqing Fan; Jeana Jaglin; Sue Leurgans; Kathleen M Shannon
Journal:  Mov Disord       Date:  2010-02-15       Impact factor: 10.338

View more
  7 in total

1.  Theory of Mind Is Impaired in Mild to Moderate Huntington's Disease Independently from Global Cognitive Functioning.

Authors:  Giovanna Lagravinese; Laura Avanzino; Alessia Raffo De Ferrari; Roberta Marchese; Carlo Serrati; Paola Mandich; Giovanni Abbruzzese; Elisa Pelosin
Journal:  Front Psychol       Date:  2017-01-26

2.  Action Semantics at the Bottom of the Brain: Insights From Dysplastic Cerebellar Gangliocytoma.

Authors:  Sabrina Cervetto; Sofía Abrevaya; Miguel Martorell Caro; Giselle Kozono; Edinson Muñoz; Jesica Ferrari; Lucas Sedeño; Agustín Ibáñez; Adolfo M García
Journal:  Front Psychol       Date:  2018-07-12

3.  Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntington's Disease Patients.

Authors:  Ashley Gutierrez; Jody Corey-Bloom; Elizabeth A Thomas; Paula Desplats
Journal:  Front Mol Neurosci       Date:  2020-01-23       Impact factor: 5.639

4.  Montreal Cognitive Assessment (MoCA) performance in Huntington's disease patients correlates with cortical and caudate atrophy.

Authors:  Gabriel Ramirez-Garcia; Victor Galvez; Rosalinda Diaz; Aurelio Campos-Romo; Juan Fernandez-Ruiz
Journal:  PeerJ       Date:  2022-04-04       Impact factor: 2.984

5.  Comparison of cognitive and UHDRS measures in monitoring disease progression in Huntington's disease: a 12-month longitudinal study.

Authors:  Eng A Toh; Michael R MacAskill; John C Dalrymple-Alford; Daniel J Myall; Leslie Livingston; Sandy Ad Macleod; Tim J Anderson
Journal:  Transl Neurodegener       Date:  2014-07-12       Impact factor: 8.014

6.  Salivary levels of total huntingtin are elevated in Huntington's disease patients.

Authors:  Jody Corey-Bloom; Ameera S Haque; Sungmee Park; Ajay S Nathan; Robert W Baker; Elizabeth A Thomas
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379

7.  Uric Acid as a Potential Peripheral Biomarker for Disease Features in Huntington's Patients.

Authors:  Jody Corey-Bloom; Ameera Haque; Sameer Aboufadel; Chase Snell; Ryan S Fischer; Steven W Granger; Douglas A Granger; Elizabeth A Thomas
Journal:  Front Neurosci       Date:  2020-03-04       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.